Mirae Asset Global Investments Co. Ltd. Raises Stock Position in Gilead Sciences, Inc. $GILD

Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 25.6% during the fourth quarter, Holdings Channel reports. The firm owned 767,449 shares of the biopharmaceutical company’s stock after buying an additional 156,615 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Gilead Sciences were worth $94,197,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in GILD. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences during the third quarter valued at $26,000. Financial Consulate Inc. raised its stake in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. BOCHK Asset Management Ltd purchased a new position in Gilead Sciences in the 4th quarter valued at about $31,000. MTM Investment Management LLC lifted its holdings in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares in the last quarter. Finally, Vision Financial Markets LLC boosted its stake in shares of Gilead Sciences by 123.1% during the 4th quarter. Vision Financial Markets LLC now owns 290 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 160 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wells Fargo reiterated a buy rating on Gilead, supporting confidence in the company’s medium‑term fundamentals and valuation. Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
• Positive Sentiment: The U.S. State Department expanded a partnership with Gilead and The Global Fund to supply 1 million doses of lenacapavir, boosting visibility and potential scale for Gilead’s HIV prevention franchise. US-Led Partnership To Provide 1 Mln Lenacapavir To Help End HIV Transmission
• Positive Sentiment: At least one Citigroup analyst publicly reiterated constructive comments about GILD’s upside, providing a counterbalance to near‑term headwinds. Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Two insiders including the CFO executed small sales (3,000 shares each) under pre‑arranged Rule 10b5‑1 plans — a liquidity event rather than an obvious signal of new negative company information. SEC Form 4 (Andrew D. Dickinson)
• Neutral Sentiment: Gilead is expected to report quarterly results soon, which typically increases volatility as investors re‑price guidance and early product trends. Gilead Sciences (GILD) Expected to Announce Quarterly Earnings on Thursday
• Neutral Sentiment: Analyst/sector coverage and valuation pieces are driving attention but haven’t changed fundamentals; this can amplify day‑to‑day flows. Gauging Gilead Sciences (GILD) Valuation After Strong Multi‑Year Shareholder Returns
• Negative Sentiment: RBC reported that persistence for Gilead’s recently launched HIV drug at nine months is weaker than expected — a potential negative for longer‑term uptake and revenue assumptions tied to the product. Gilead Sciences’ HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says
• Negative Sentiment: Zacks Research trimmed Q1–Q4 and full‑year FY2026 EPS forecasts, lowering near‑term earnings expectations and increasing downside risk to consensus. Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Broader health‑care sector weakness pressured stocks late in the session, amplifying selling pressure on GILD despite company‑specific positives. Sector Update: Health Care Stocks Decline Late Afternoon

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the transaction, the chief financial officer directly owned 176,191 shares in the company, valued at $24,835,883.36. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the transaction, the chief executive officer directly owned 642,308 shares in the company, valued at $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 299,280 shares of company stock worth $42,920,450 over the last three months. 0.30% of the stock is owned by insiders.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $138.55 on Friday. The company has a market cap of $171.97 billion, a P/E ratio of 20.47, a P/E/G ratio of 1.86 and a beta of 0.39. The firm’s 50 day moving average is $144.65 and its two-hundred day moving average is $131.10. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on GILD shares. Citigroup boosted their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday. Mizuho lifted their target price on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Barclays assumed coverage on Gilead Sciences in a report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target for the company. Wells Fargo & Company raised their price objective on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Finally, BMO Capital Markets lifted their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $156.77.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.